News from the healthcare data industry
September 4, 2024 PDF Version The strategic collaboration will leverage Tempus’ large multimodal datasets to enhance BioNTech’s next-generation oncology pipeline CHICAGO–(BUSINESS WIRE)–Sep. 4, 2024– Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology...
Tempus invests $36 million by exercising warrants and purchasing additional shares August 16, 2024 08:30 AM Eastern Daylight Time FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq:...
Tempus AI, Inc. (“Tempus”) today announced the pricing of its initial public offering of 11,100,000 shares of its Class A common stock at a public offering price of $37.00 per...
April 16, 2024 09:30 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, is introducing Tempus Next, a care pathway intelligence platform. By harnessing the...
Lens is trusted by nearly 100 institutions to uncover novel insights April 06, 2024 09:30 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, is...
Featuring Ira Klein, MD, MBA 02/07/2024 Ira Klein, MD, MBA, vice president of medical affairs for Tempus Labs, provides insight into the future of AI in health care and how it...
November 28, 2023 04:15 PM Eastern Standard Time FREMONT, Calif. & CHICAGO–(BUSINESS WIRE)–Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in...
Tempus, a leader in artificial intelligence and precision medicine, today announced that City of Hope Comprehensive Cancer Center has joined Tempus+, a proprietary program that powers collaborative precision oncology research through...
SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced two significant updates with...
November 08, 2023 09:00 AM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic research collaboration with Bristol Myers Squibb (NYSE:...